Table 2.

Pretreatment characteristics

Patient or Tumor Characteristic	≤3 wk		>3–4 wk		>4 wk		P-value
	n	%	n	%	n	%
Days from surgery to start of RT
Median	19		26		33
Min–Max	0–21		22–28		29–68
Q1–Q3	16–21		24–27		31–35
RT dose							0.42**
Median	60		60		60
Min–Max	22–60.14		4–64		2–62
Q1–Q3	60–60		60–60		60–60
Age, y							0.24**
Median	59		58		57
Min–Max	22–87		19–84		20–84
Q1–Q3	51–66		50–65		50–65
Sex							0.21*
Male	105	56.5	286	61.6	423	56.8
Female	81	43.5	178	38.4	322	43.2
Karnofsky performance status							0.32*
60	11	5.9	17	3.7	33	4.4
70	23	12.4	57	12.3	89	11.9
80	37	19.9	115	24.8	152	20.4
90	87	46.8	183	39.4	311	41.7
100	28	15.1	92	19.8	160	21.5
Surgery	Partial vs total resection						0.003*
Partial resection	82	44.1	171	36.9	346	46.4
Total resection	89	47.8	277	59.7	373	50.1
Other	15	8.1	16	3.4	26	3.5
Neurologic function	No vs minor vs moderate/severe symptoms						0.04*
No symptoms	46	24.7	141	30.4	260	34.9
Minor symptoms	101	54.3	218	47.0	320	43.0
Moderate symptoms	39	21.0	103	22.2	161	21.6
Severe symptoms	0	0.0	2	0.4	4	0.5
RPA	RPA III vs IV vs V						0.53*
III	28	15.1	77	16.6	138	18.5
IV	111	59.7	288	62.1	450	60.4
V	47	25.3	96	20.7	152	20.4
Unknown	0	0.0	3	0.6	5	0.7
MGMT status	Methylated vs unmethylated						0.70*
Methylated	46	24.7	120	25.9	209	28.1
Unmethylated	105	56.5	267	57.5	422	56.6
Unknown (indeterminate, invalid)	16	8.6	31	6.7	49	6.6
Insufficient tissue	18	9.7	40	8.6	57	7.7
Not done	1	0.5	6	1.3	8	1.1
Radiotherapy delivery declared at registration							<0.001*
RTOG RT#	178	95.7	438	94.4	618	83.0
EORTC RT##	8	4.3	26	5.6	127	17.0
Study number							<0.001*
RTOG 0525	173	93.0	345	74.4	561	75.3
RTOG 0825	13	7.0	119	25.6	184	24.7
Total	186	100.0	464	100.0	745	100.0

*Chi-square test.

**Kruskal–Wallis test.

# RTOG RT: RTOG radiation guidelines assume a 2-phase plan (46 + 14 = 60 Gy), with a wider field in most cases, that includes the “edema”/infiltrative non-enhancing tumor: T2 area of hyperintensivity + T1 enhancing residual tumor + resection cavity + a 2 cm margin.

## EORTC RT: EORTC radiation guidelines assume a 1-phase planned clinical target volume to treat T1 enhancing residual tumor + resection cavity + a 2–3 cm margin.